754 related articles for article (PubMed ID: 32943410)
1. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Nasser M; Larrieu S; Si-Mohamed S; Ahmad K; Boussel L; Brevet M; Chalabreysse L; Fabre C; Marque S; Revel D; Thivolet-Bejui F; Traclet J; Zeghmar S; Maucort-Boulch D; Cottin V
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32943410
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
5. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
7. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
[TBL] [Abstract][Full Text] [Related]
8. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
Joung KI; Park H; Park S; Shin JY; Kim YH
BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
[TBL] [Abstract][Full Text] [Related]
9. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
[TBL] [Abstract][Full Text] [Related]
10. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
11. Lung function trajectory in progressive fibrosing interstitial lung disease.
Oldham JM; Lee CT; Wu Z; Bowman WS; Pugashetti JV; Dao N; Tonkin J; Seede H; Echt G; Adegunsoye A; Chua F; Maher TM; Garcia CK; Strek ME; Newton CA; Molyneaux PL
Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737223
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
13. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
14. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
15. Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease.
Niitsu T; Fukushima K; Komukai S; Takata S; Abe Y; Nii T; Kuge T; Iwakoshi S; Shiroyama T; Miyake K; Tujino K; Tanizaki S; Iwahori K; Hirata H; Miki K; Yanagawa M; Takeuchi N; Takeda Y; Kida H; Kumanogoh A
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36690385
[TBL] [Abstract][Full Text] [Related]
16. Real-life prevalence of progressive fibrosing interstitial lung diseases.
Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
[TBL] [Abstract][Full Text] [Related]
19. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
20. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]